Advanced search
Publication Cover
Expert Review of Gastroenterology & Hepatology Volume 7, 2013 - Issue sup1
Submit an article Journal homepage
100
Views
2
CrossRef citations to date
0
Altmetric
Symposium Paper

Management of irritable bowel syndrome with constipation: a flexible approach to treating a complex condition with multiple symptoms

Peter Layer Medizinische Klinik, Israelitisches Krankenhaus in Hamburg, Orchideenstieg 14, 22297 Hamburg, Germany. [email protected]
Pages 9-14 | Published online: 10 Jan 2014

References

  • Posserud I, Ersryd A, Simrén M. Functional findings in irritable bowel syndrome. World J. Gastroenterol. 12(18), 2830–2838 (2006).
  • Sinhamahapatra P, Saha SP, Chowdhury A, Chakrabarti SK, Ghosh A, Maiti B. Visceral afferent hypersensitivity in irritable bowel syndrome – evaluation by cerebral evoked potential after rectal stimulation. Am. J. Gastroenterol. 96(7), 2150–2157 (2001).
  • Quigley EM. Changing face of irritable bowel syndrome. World J. Gastroenterol. 12(1), 1–5 (2006).
  • Chang L. Review article: epidemiology and quality of life in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 20(Suppl. 7), 31–39 (2004).
  • Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 130(5), 1480–1491 (2006).
  • Gwee KA, Graham JC, McKendrick MW et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 347(8995), 150–153 (1996).
  • Ruigomez A, Wallander MA, Johansson S, Garcia Rodriguez LA. One-year follow-up of newly diagnosed irritable bowel syndrome patients. Aliment. Pharmacol. Ther. 13(8), 1097–1102 (1999).
  • Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 51(3), 410–413 (2002).
  • Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. Br. Med. J. 314(7083), 779–782 (1997).
  • Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 136(6), 1979–1988 (2009).
  • Gwee KA, Collins SM, Read NW et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome. Gut 52(4), 523–526 (2003).
  • Macsharry J, O’Mahony L, Fanning A et al. Mucosal cytokine imbalance in irritable bowel syndrome. Scand. J. Gastroenterol. 43(12), 1467–1476 (2008).
  • Guilarte M, Santos J, de Torres I et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut 56(2), 203–209 (2007).
  • Barbara G, Stanghellini V, De Giorgio R et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126(3), 693–702 (2004).
  • Owens DM, Nelson DK, Talley NJ. The irritable bowel syndrome: long-term prognosis and the physician–patient interaction. Ann. Intern. Med. 122(2), 107–112 (1995).
  • Brandt LJ, Chey WD, Foxx-Orenstein AE et al. An evidence-based position statement on the management of irritable bowel syndrome. American College of Gastroenterology IBS Task Force. Am. J. Gastroenterol. 104(Suppl. 1), S1–S35 (2009).
  • Layer P, Andresen V, Pehl C et al. [Irritable bowel syndrome: German consensus guidelines on definition, pathophysiology and management]. Z. Gastroenterol. 49(2), 237–293 (2011).
  • Ford AC, Forman D, Bailey AG, Axon AT, Moayyedi P. Irritable bowel syndrome: a 10-yr natural history of symptoms and factors that influence consultation behavior. Am. J. Gastroenterol. 103(5), 1229–1239 (2008).
  • Zijdenbos IL, de Wit NJ, van der Heijden GJ, Rubin G, Quartero AO. Psychological treatments for the management of irritable bowel syndrome. Cochrane Database Syst. Rev. (1), CD006442 (2009).
  • Ruepert L, Quartero AO, de Wit NJ, van der Heijden GJ, Rubin G, Muris JW. Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (8), CD003460 (2011).
  • Gorard DA, Libby GW, Farthing MJ. Influence of antidepressants on whole gut and orocaecal transit times in health and irritable bowel syndrome. Aliment. Pharmacol. Ther 8(2), 159–166 (1994).
  • Ladabaum U, Sharabidze A, Levin TR et al. Citalopram provides little or no benefit in nondepressed patients with irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 8(1), 42–48 (2010).
  • Johannesson E, Simren M, Strid H, Bajor A, Sadik R. Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial. Am. J. Gastroenterol. 106(5), 915–922 (2011).
  • Park MI, Camilleri M. Is there a role of food allergy in irritable bowel syndrome and functional dyspepsia? A systematic review. Neurogastroenterol. Motil. 18(8), 595–607 (2006).
  • Biesiekierski JR, Newnham ED, Irving PM et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: a double-blind randomized placebo-controlled trial. Am. J. Gastroenterol. 106(3), 508–514 (2011).
  • Spiller R, Aziz Q, Creed F et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut 56, 1770–1798 (2007).
  • Su A, Chang L. IBS bowel habits and associated symptoms: forming a clearer picture. Gastroenterology 144(1), 239–242 (2013).
  • Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. Am. J. Gastroenterol. 107(2), 286–295 (2012).
  • Khoshoo V, Armstead C, Landry L. Effect of a laxative with and without tegaserod in adolescents with constipation predominant irritable bowel syndrome. Aliment. Pharmacol. Ther. 23(1), 191–196 (2006).
  • Quartero AO, Meineche-Schmidt V, Muris J, Rubin G, de Wit N. Bulking agents, antispasmodic and antidepressant medication for the treatment of irritable bowel syndrome. Cochrane Database Syst. Rev. (2), CD003460 (2005).
  • Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet 344(8914), 39–40 (1994).
  • Gonlachanvit S, Coleski R, Owyang C, Hasler W. Inhibitory actions of a high fibre diet on intestinal gas transit in healthy volunteers. Gut 53(11), 1577–1582 (2004).
  • Bijkerk CJ, Muris JW, Knottnerus JA, Hoes AW, de Wit NJ. Systematic review: the role of different types of fibre in the treatment of irritable bowel syndrome. Aliment. Pharmacol. Ther. 19(3), 245–251 (2004).
  • Barbara G, Stanghellini V, Cremon C et al. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J. Clin. Gastroenterol. 42(Suppl. 3 Pt 2), S214–S217 (2008).
  • Hosseini A, Nikfar S, Abdollahi M. Are probiotics effective in management of irritable bowel syndrome? Arch. Med. Sci. 8(3), 403–405 (2012).
  • Quigley EM. Probiotics in the management of functional bowel disorders: promise fulfilled? Gastroenterol. Clin. North Am. 41(4), 805–819 (2012).
  • Moayyedi P, Ford AC, Talley NJ et al. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut 59(3), 325–332 (2010).
  • Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst. Rev. (7), CD007570 (2010).
  • Tort S, Balboa A, Marzo M et al. [Clinical practice guideline for irritable bowel syndrome]. Gastroenterol. Hepatol. 29(8), 467–521 (2006).
  • Ford AC, Talley NJ, Spiegel BMR et al. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. Br. Med. J. 337, a2313 (2008).
  • Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in Asian patients with irritable bowel syndrome. J. Neurogastroenterol. Motil. 17(4), 402–410 (2011).
  • Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N. Engl. J. Med. 358(22), 2344–2354 (2008).
  • Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation – a 12-week, randomized, double-blind, placebo-controlled study. Aliment. Pharmacol. Ther. 29(3), 315–328 (2009).
  • Tack J, van Outryve M, Beyens G, Kerstens R, Vandeplassche L. Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives. Gut 58(3), 357–365 (2009).
  • Drossman DA, Chey WD, Johanson JF et al. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome – results of two randomized, placebo-controlled studies. Aliment. Pharmacol. Ther. 29(3), 329–341 (2009).
  • Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 27(8), 685–696 (2008).
  • Chey WD, Drossman DA, Johanson JF, Scott C, Panas RM, Ueno R. Safety and patient outcomes with lubiprostone for up to 52 weeks in patients with irritable bowel syndrome with constipation. Aliment. Pharmacol. Ther. 35(5), 587–599 (2012).
  • Chey WD, Lembo AJ, Lavins BJ et al. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am. J. Gastroenterol. 107, 1702–1712 (2012).
  • Quigley EMM, Tack J, Choi HS et al. Randomised clinical trials: linaclotide Phase 3 studies in IBS-C – a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment. Pharmacol. Ther. 37(1), 49–61 (2013).
  • Rao S, Lembo AJ, Shiff SJ et al. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. Am. J. Gastroenterol. 107, 1714–1724 (2012).
  • Tack J. How can we achieve relief of bowel and abdominal symptoms for patients with IBS with constipation? Expert Rev. Gastroenterol. Hepatol. 7(5 Suppl. 1), 21–26 (2013).
  • Blackshaw LA and Brierley SM. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation. Expert Rev. Gastroenterol. Hepatol. 7(5 Suppl. 1), 15–19 (2013).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.